Most Recent
Celgene sues to protect patents for blockbuster cancer drug Revlimid
Intellectual Property 2021-11-22 4:10 pm By Cindy Cameronne

Bristol-Myers Squib unit Celgene Corporation has sued Indian generics giant Dr Reddy’s Laboratories for allegedly threatening to infringe eight patents for its blockbuster cancer drug Revlimid, which raked in US$12 billion for the US-based company in revenue last year.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Latest patent ruling rejecting AI inventorship puts Federal Court in minority
Intellectual Property 2021-09-24 1:58 pm By Miklos Bolza

The Federal Court’s decision that artificial intelligence can be listed on a patent application as the inventor has become an outlier, as the UK joins the US in rejecting what has become an international battle to claim AI inventorship.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Pharmacor challenges patent extension for Biogen’s MS drug
Intellectual Property 2021-09-23 2:14 pm By Bianca Hrovat

An Australian generic drug manufacturer has struck back at patent lawsuit by Swiss pharmaceutical company Biogen, alleging a patent for MS drug Tecfidera is invalid and a that a patent term extension for the drug  was wrongly granted.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Merck Sharp & Dohme appeals judgment tossing Januvia patent extension
Intellectual Property 2021-09-10 6:04 pm By Miklos Bolza

Merck Sharp & Dohme is seeking to overturn a judgment refusing an extension of a patent covering its Januvia and Janumet diabetes drugs that would have seen the US drug maker of retaining a monopoly over the multibillion dollar medicines beyond July 2022.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Commissioner of Patents challenges landmark ruling on artificial intelligence
Appeals 2021-08-30 1:47 pm By Cat Fredenburgh

The Commissioner of Patents has appealed a landmark judgment that found artificial intelligence can be named an inventor on a patent application.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Biogen wants injunction ahead of trial against Pharmacor over MS drug
Intellectual Property 2021-08-25 2:25 pm By Cindy Cameronne

Swiss pharmaceutical company Biogen is seeking a court order blocking an Australian generic drug manufacturer from selling a cheap multiple sclerosis drug it claims infringes its patent for medicine Tecfidera, a court has heard.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Court throws out Merck Sharp & Dohme’s Januvia patent extension
Intellectual Property 2021-08-12 2:29 pm By Miklos Bolza

The Federal Court has dealt US drug giant Merck Sharp & Dohme a devastating blow, overturning an “untenable” patent term extension which would have protected the monopoly of its multibillion-dollar Januvia and Janumet diabetes drugs beyond July 2o22.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

‘Why cannot our own creations also create?’: AI can be inventor on patent, court finds
Intellectual Property 2021-07-30 12:39 pm By Cat Fredenburgh

A judge has found artificial intelligence can be named as the inventor on a patent application, setting aside an IP Australia finding that allowing a machine to be considered an inventor would render the Patents Act incapable of “sensible operation”.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

After GetSwift, judge could not hear split trial in Revlimid patent case, court told
Intellectual Property 2021-07-20 8:39 pm By Christine Caulfield

A proposal by Bristol-Myers Squibb-owned Celgene to split a second trial into two more hearings in a dispute over patents covering the pharmaceutical maker’s top selling cancer drug Revlimid would result in wasted costs, wasted time and require a second judge, a court has been told.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?

Juno and Bristol-Myers Squibb suffer losses in Revlimid patent war
Intellectual Property 2021-03-25 1:58 pm By Miklos Bolza

A patent battle between Juno Pharmaceuticals and Bristol-Myers Squibb over the blockbuster drug Revlimid has seen both sides suffer early losses, with a judge dismissing strike out and summary dismissal applications by the drug makers.

Subscribe to Lawyerly to access this article.

Already a subscriber?

Lost your password?